rs149782619
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PM2PP5_Very_Strong
The ENST00000304043.10(HINT1):c.110G>C(p.Arg37Pro) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000222 in 1,613,686 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R37Q) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000304043.10 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HINT1 | NM_005340.7 | c.110G>C | p.Arg37Pro | missense_variant, splice_region_variant | 1/3 | ENST00000304043.10 | NP_005331.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HINT1 | ENST00000304043.10 | c.110G>C | p.Arg37Pro | missense_variant, splice_region_variant | 1/3 | 1 | NM_005340.7 | ENSP00000304229 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000315 AC: 48AN: 152206Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000260 AC: 65AN: 250326Hom.: 0 AF XY: 0.000310 AC XY: 42AN XY: 135420
GnomAD4 exome AF: 0.000212 AC: 310AN: 1461362Hom.: 0 Cov.: 32 AF XY: 0.000245 AC XY: 178AN XY: 727010
GnomAD4 genome AF: 0.000315 AC: 48AN: 152324Hom.: 0 Cov.: 32 AF XY: 0.000362 AC XY: 27AN XY: 74492
ClinVar
Submissions by phenotype
Autosomal recessive axonal neuropathy with neuromyotonia Pathogenic:10
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Nov 14, 2023 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2012 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 23, 2023 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Institute of Human Genetics, Cologne University | Apr 25, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Oct 02, 2019 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PM1,PP2,PP5. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Aug 02, 2024 | Criteria applied: PM3_VSTR,PS4_SUP,PM2_SUP - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Sep 06, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Feb 23, 2023 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.030%). Missense changes are a common disease-causing mechanism. Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000037312). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 4 similarly affected unrelated individuals (PMID: 22961002, 22961002, 26182879, 27549087). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 29, 2023 | This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 37 of the HINT1 protein (p.Arg37Pro). This variant is present in population databases (rs149782619, gnomAD 0.09%). This missense change has been observed in individuals with clinical features of distal hereditary motor neuropathy (PMID: 22961002, 25342199, 26182879, 27549087). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 37312). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The observed missense c.110G>C (p.Arg37Pro) variant in HINT1 gene has been reported previously in homozygous and compound heterozygous states in multiple individuals affected with neuromyotonia and axonal neuropathy (Zimon et al., 2012; Laššuthová et al., 2015; Jerath et al., 2015; Laššuthová et al., 2016). It has also been observed to segregate with disease in related individuals. Functional studies demonstrate this variant to cause loss of enzyme function (Zimon et al., 2012). This variant is present with allele frequency of 0.03% in gnomAD Exomes. This variant has been submitted to the ClinVar database as Pathogenic (multiple submissions). Computational evidence (Polyphen - Benign, SIFT - Tolerated and MutationTaster - Disease causing) predicts conflicting evidence on protein structure and function for this variant. The reference amino acid of p.Arg37Pro in HINT1 is predicted as conserved by PhyloP across 100 vertebrates. The amino acid Arg at position 37 is changed to a Pro changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 19, 2022 | Published functional studies demonstrate loss of enzyme function in the homozygous state (Zimon et al., 2012); Reported as a founder mutation in the Czech population, accounting for 95% of pathogenic alleles (Lassuthova et al., 2015).; In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 26182879, 32709422, 22961002, 24918641, 25342199, 26194197, 23043279, 27549087, 29787766, 31787464, 31848916, 34562060, 33726816, 34694653, 33663550) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2024 | HINT1: PM3:Very Strong, PP1:Strong, PM2, PS3:Supporting, BP4 - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 23, 2022 | The c.110G>C (p.R37P) alteration is located in exon 1 (coding exon 1) of the HINT1 gene. This alteration results from a G to C substitution at nucleotide position 110, causing the arginine (R) at amino acid position 37 to be replaced by a proline (P). Based on data from the Genome Aggregation Database (gnomAD), the HINT1 c.110G>C alteration was observed in 0.03% (85/281,678) of total alleles studied. The p.R37P alteration, one of three founder mutations and considered to be the most common, has been reported in homozygous and compound heterozygous individuals with autosomal recessive axonal neuropathy with neuromyotonia (Zimo, 2012; Laššuthová, 2015; Jerath, 2015; Shchagina, 2020). This amino acid position is poorly conserved in available vertebrate species. Protein contain p.R37P fails to form functional dimers and exists as monomers, which showed significant loss of secondary structure compared to wild type and showed reduced near UV-absorption indicating incorrect or improper folding (Shah, 2018). This alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Peripheral neuropathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at